Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Liabilities and Shareholders Equity (2016 - 2025)

Arcadia Biosciences' Liabilities and Shareholders Equity history spans 12 years, with the latest figure at $6.5 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 51.57% year-over-year to $6.5 million; the TTM value through Dec 2025 reached $35.9 million, down 42.25%, while the annual FY2025 figure was $6.5 million, 51.57% down from the prior year.
  • Liabilities and Shareholders Equity reached $6.5 million in Q4 2025 per RKDA's latest filing, down from $8.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $70.8 million in Q1 2021 to a low of $6.5 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $29.0 million, with a median of $25.1 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 119.55% in 2021, then crashed 55.16% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $43.9 million in 2021, then tumbled by 34.15% to $28.9 million in 2022, then tumbled by 31.87% to $19.7 million in 2023, then tumbled by 31.4% to $13.5 million in 2024, then plummeted by 51.57% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Liabilities and Shareholders Equity are $6.5 million (Q4 2025), $8.6 million (Q3 2025), and $7.8 million (Q2 2025).